First lineup of THCV products enabled by
Organigram’s strategic investment in Phylos Bioscience
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the
“Company” or “Organigram”), a leading licensed producer of
cannabis, is pleased to launch its first range of whole-flower
derived THCV products through the Company’s popular SHRED and newly
re-launched Trailblazer brands.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230828932090/en/
THCV Now Available in Canada. (Graphic:
Business Wire)
Reaffirming its commitment to forward-looking innovation,
Organigram strives to maintain a competitive advantage in the
cannabis industry, most recently through its strategic investment
in Phylos Bioscience, a US-based leader in cannabis genetics.
Through this investment, Organigram cultivates and extracts THCV
in-house in its state-of-the-art Moncton facility and is currently
believed to be the only Canadian licensed producer (LP) to do
so.
THCV is a novel and rare cannabinoid often referenced for its
appetite suppressing effects1. THCV is a compelling offering for
consumers because, like CBD, it is reported to be non-psychoactive
2, and acts as an antagonist for some of the qualities associated
with THC. For example, THCV is reported to mitigate the appetite
stimulation 1 associated with THC, earning it the nickname “Diet
Weed”, and is also gaining popularity for its reported ‘super
sativa’ effects of wellness, energy and focus.2
Organigram has exclusive Canadian rights to all THCV cultivars
from Phylos, including Get S**t Done (1:3 THC:THCV) and Joyride
(1:1 THC:THCV), two popular cultivars with THCV concentrations that
are significantly higher than anything else currently available in
the market. Phylos has developed, and continues to develop,
proprietary high-THCV genetics in various THC:THCV ratios where
each ratio creates a differentiated user experience and can be
delivered in a wide range of product formats.
“At Organigram, our commitment to scientific excellence,
rigorous research, and consumer-driven innovation sets us apart in
the industry,” says Borna Zlamalik, Senior Vice President of
Innovation and R&D at Organigram. “We are currently the only
licensed Canadian cannabis company to be cultivating and extracting
from THCV flower, meaning that our products are made from the
entire cannabis flower, including cannabinoids, terpenes,
flavonoids, and other compounds. They are extracted directly from
the cannabis plant using methods like CO2 and solventless cold
water extraction. Our products are naturally (and not
synthetically) derived, not created through chemical processes in a
laboratory setting. This is a testament to our extraordinary
R&D, exceptional talent, and the incredible capabilities we
have in-house,” he added.
Organigram’s first THCV range of products include:
- SHRED’ems Guava Lime Go–Time: This exotic new flavour
profile, bursting with guava and lime flavours provides a unique
cannabinoid experience with an initial 1:1 THC:THCV (10mg THC +
10mg THCV) ratio per pack. An entry point for those looking to
experience this new minor cannabinoid.
- Trailblazer Zen Garden Grapefruit: A THCV-forward,
grapefruit flavoured sugar-free gummy, that offers more THCV than
any other gummy in the market with an initial 1:2 THC:THCV (10mg
THC + 20mg THCV) ratio per pack.
“In this era of heightened awareness, we recognize that
consumers expect more from cannabis producers, and our commitment
as an industry-leading Licensed Producer is to exceed those
expectations. By harnessing the power of THCV through our strategic
investment, we are reshaping the cannabis experience for
consumers,” says Megan McCrae, Senior Vice President of Marketing
and Communications at Organigram.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select Market and
TSX listed company whose wholly owned subsidiaries include:
Organigram Inc. and Laurentian Organic Inc., licensed producers of
cannabis and cannabis-derived products in Canada, and The Edibles
and Infusions Corporation, a licensed manufacturer of
cannabis-infused edibles in Canada. Organigram is focused on
producing high-quality, cannabis for patients and adult
recreational consumers, as well as developing international
business partnerships to extend the Company’s global footprint.
Organigram has also developed and acquired a portfolio of legal
adult-use recreational cannabis brands, including Edison, Holy
Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian,
Tremblant Cannabis and Trailblazer. Organigram operates facilities
in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a
dedicated edibles manufacturing facility in Winnipeg, Manitoba. The
Company is regulated by the Cannabis Act and the Cannabis
Regulations (Canada).
Forward-Looking Information
This news release contains forward-looking information. Often,
but not always, forward-looking information can be identified by
the use of words such as “plans”, “expects”, “estimates”,
“intends”, “anticipates”, “believes” or variations of such words
and phrases or state that certain actions, events, or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. Forward-looking information involves known and unknown
risks, uncertainties and other factors that may cause actual
results, events, performance or achievements of Organigram to
differ materially from current expectations or future results,
performance or achievements expressed or implied by the
forward-looking information contained in this news release. Risks,
uncertainties and other factors involved with forward-looking
information could cause actual events, results, performance,
prospects and opportunities to differ materially from those
expressed or implied by such forward-looking information include
changes to market conditions, consumer preferences and regulatory
climate including change in regulation of minor cannabinoids such
as THC-V, and factors and risks as disclosed in the Company’s most
recent annual information form, management’s discussion and
analysis and other Company documents filed from time to time on
SEDAR (see www.sedar.com) and filed or furnished to the Securities
and Exchange Commission on EDGAR (see www.sec.gov). Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Although the Company believes that the assumptions and factors used
in preparing the forward-looking information in this news release
are reasonable, undue reliance should not be placed on such
information and no assurance can be given that such events will
occur in the disclosed time frames or at all. The forward-looking
information included in this news release are made as of the date
of this news release and the Company disclaims any intention or
obligation, except to the extent required by law, to update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise.
Footnotes:
- Jadoon, Khalid A et al. “Efficacy and Safety of Cannabidiol and
Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients
With Type 2 Diabetes: A Randomized, Double-Blind,
Placebo-Controlled, Parallel Group Pilot Study.” Diabetes care vol.
39,10 (2016): 1777-86. doi:10.2337/dc16-0650
https://pubmed.ncbi.nlm.nih.gov/27573936/
- Cascio, Maria Grazia et al. “The phytocannabinoid,
Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to
produce antipsychotic effects.” British journal of pharmacology
vol. 172,5 (2015): 1305-18. doi:10.1111/bph.13000
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337703/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230828932090/en/
For Investor Relations enquiries: Max Schwartz
Director of Investor Relations investors@organigram.ca Organigram
For Media enquiries: Megan McCrae Senior Vice
President of Marketing and Communications
megan.mccrae@organigram.ca Organigram
Organigram (NASDAQ:OGI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Organigram (NASDAQ:OGI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024